ClinicalTrials.gg
CompletedNCT07933341Updated Nov 12, 2026

LH-Guided Recombinant LH Supplementation in Women Undergoing IVF/ICSI

An observational study in Infertility, Infertility (IVF Patients) and Infertility Assisted Reproductive Technology, sponsored by Stella Maris Women and Children Hospital. Completed at 1 site in Indonesia. Open to female participants aged 21 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Stella Maris Women and Children Hospital · Observational

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
395
Ages
21 Years to 45 Years
Sex
Female
01

Study summary

The goal of this observational study is to evaluate the relationship between luteinizing hormone (LH)-guided recombinant LH supplementation and IVF outcomes in women aged 21-45 years undergoing their first IVF/ICSI cycle using a gonadotropin-releasing hormone (GnRH) antagonist protocol.

The main questions it aims to answer are:

  • Is LH-guided recombinant LH supplementation associated with a higher number of good-quality blastocysts?
  • Is LH-guided recombinant LH supplementation associated with a higher clinical pregnancy rate?

Researchers will compare two groups of women:

Group A (LH-Guided Supplementation): Women with serum LH levels below 1.2 mIU/mL on menstrual cycle day 2 or stimulation day 5 (corresponding to menstrual cycle day 6) who received recombinant LH supplementation at 75 IU/day until ovulation triggering.

Group B (No LH Supplementation): Women with serum LH levels of 1.2 mIU/mL or higher at both assessments who underwent standard ovarian stimulation without recombinant LH supplementation.

02

Conditions studied

  • Infertility
  • Infertility (IVF Patients)
  • Infertility Assisted Reproductive Technology

Browse trials for

03

In context

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

This study's enrollment of 395 is above the median of 200 across 592 observational studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Stella Maris Women and Children Hospital is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

The study population consisted of women receiving fertility treatment at Halim Fertility Center, Medan, Indonesia. Participants were identified retrospectively from the center's medical records of IVF/ICSI treatment cycles conducted between January and December 2023. The study evaluated patients who underwent ovarian stimulation using a GnRH antagonist protocol as part of routine clinical care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 21-45 years.
  • Undergoing their first IVF/ICSI cycle using a GnRH antagonist protocol.
  • (BMI) between 18 and 35 kg/m².
  • Normal uterine cavity based on available clinical assessments.

Exclusion criteria

Exclusion Criteria:

  • History of previous IVF cycles.
  • Thyroid-stimulating hormone (TSH) level above 4.5 mIU/L.
  • Prolactin level above 25 ng/mL.
  • Uterine abnormalities identified during clinical evaluation.
  • Severe male-factor infertility, defined as sperm concentration below 1 × 10⁶/mL.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
395 participants (actual)
Patient registry
No

Groups and cohorts

  • LH-Guided Recombinant LH Supplementation Group

    This cohort included 154 women undergoing their first IVF/ICSI cycle using a GnRH antagonist protocol who had serum luteinizing hormone (LH) levels below 1.2 mIU/mL on menstrual cycle day 2 or stimulation day 5 (corresponding to menstrual cycle day 6). As part of routine clinical care, these patients received recombinant LH supplementation at a dose of 75 IU/day, starting when low LH was identified and continuing until ovulation triggering. Embryological outcomes and clinical pregnancy rates were retrospectively evaluated.

  • No Recombinant LH Supplementation Group

    This cohort included 241 women undergoing their first IVF/ICSI cycle using a GnRH antagonist protocol who had serum luteinizing hormone (LH) levels of 1.2 mIU/mL or higher at both menstrual cycle day 2 and stimulation day 5 (corresponding to menstrual cycle day 6). These patients underwent standard ovarian stimulation without recombinant LH supplementation as part of routine clinical care. Embryological outcomes and clinical pregnancy rates were retrospectively evaluated.

06

What researchers measure

Primary outcomes

  1. Number of good-quality blastocysts per IVF/ICSI cycle

    The primary outcome was the number of good-quality blastocysts obtained per IVF/ICSI cycle. Blastocyst quality was assessed using the Gardner grading system. Good-quality blastocysts were defined as blastocysts with an expansion grade of 4-6 and inner cell mass (ICM) and trophectoderm (TE) grades of AA, AB, or BA. The number of good-quality blastocysts per cycle was compared between women who received LH-guided recombinant LH supplementation and those who did not receive supplementation.

    Time frame: At blastocyst assessment, 5-6 days after oocyte retrieval

Secondary outcomes

  1. Clinical pregnancy rate confirmed by transvaginal ultrasonography

    The secondary outcome was the clinical pregnancy rate following IVF/ICSI treatment. Clinical pregnancy was defined as the ultrasonographic visualization of one or more gestational sacs. Serum beta-human chorionic gonadotropin (β-hCG) was measured 10 days after blastocyst transfer, followed by transvaginal ultrasonography approximately 2 weeks after biochemical pregnancy confirmation. The clinical pregnancy rate was calculated as the percentage of women with a confirmed clinical pregnancy among all women who underwent embryo transfer in each study group.

    Time frame: Approximately 24 days after blastocyst transfer

07

Study locations

1 site
  • RSIA Stella Maris
    Medan, North Sumatra 20152, Indonesia
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Dec 2023, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 12, 2026
StartActual
Jan 1, 2023
Primary completionActual
Dec 31, 2023
CompletionActual
Dec 31, 2023
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07933341
Lead sponsor
Stella Maris Women and Children Hospital
Collaborators
Halim Fertility Center, Universitas Sumatera Utara, Universitas Prima Indonesia
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Jan 1, 2023
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion